HOSPITAL-ACQUIRED URINARY TRACT INFECTIONS IN CANCER PATIENTS

Introduction. Urinary tract infections are among the most frequently seen bacterial infections. Worldwide, about 150 million people are diagnosed with urinary tract infections each year, costing the global economy in excess of 3.5 billion US dollars. Urinary tract infections occur more frequently and exhibit more severe symptoms in cancer patients than in patients with other diseases. Material and methods. The paper analyzes the etiology of urinary tract infections in cancer patients during their stay in the hospital. Results. The presented data concern antibiotic-resistant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). Comparative data on the sensitivity to different antibiotics were shown. Recommendations for treatment aimed at reducing the selective pressure of certain groups of antibiotics, in particular carbapenems, were given.

1. Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015 May; 13 (5): 269–84. doi: 10.1038/ nrmicro3432.

2. Grigorievskaya Z.V. The strategy of treatment of nosocomial infections caused by resistant microorganisms in the oncology clinic [doctoral thesis]. [Moscow]; 2015. 252. [in Russian]

3. Petukhova I.N., Grigorievskaya Z.V., Dmitrieva N.V. Wound infections in urologic oncology. Siberian Journal of Oncology. 2014; 5: 60–6. [in Russian]

4. Petukhova I.N., Dmitrieva N.V. Urinary tract infections in cancer patients. Malignant Tumors. 2014; (3): 160–16. [in Russian]

5. Petukhova I.N., Dmitrieva N.V. Therapy for urinary tract infections. Urologic Oncology. Moscow, 2014. 469–498. [in Russian]

6. Petukhova I.N., Dmitrieva N.V. Antibicrobal Therapy of Hospital-Acquired Infections. Moscow: АBV Press, 2015. P. 294–303. [in Russian]

7. Arias C.A., Murray B.E. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012 Mar 16; 10 (4): 266–78. doi: 10.1038/nrmicro2761.

8. Kostakioti M., Hultgren S.J., Hadjifrangiskou M. Molecular blueprint of uropathogenic Escherichia coli virulence provides clues toward the development of anti-virulence therapeutics. Virulence. 2012 Nov 15; 3 (7): 592–4. doi: 10.4161/viru.22364.

9. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar; 28 (1): 1–13. doi: 10.1016/j.idc.2013.09.003.

10. Lo E., Nicolle L.E., Coffin S.E., Gould C., Maraqakis L.L., Med-dinqs J., Peques D.A., Pettis A.M., Saint S., Yokoe D.S. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014 Sep; 35 Suppl 2: S32–47.